The present invention relates to a column comprising a vascular endothelial growth factor (VEGF) dimer molecule, a method for preparing such a column, a VEGF dimer molecule, an expression vector and a recombinant host cell encoding for a VEGF dimer, as well as uses and methods related thereto.

A method for performing apheresis of mammals, including humans, is set forth which does not require separation of the blood into plasma or any other portion. Termed whole blood apheresis herein, this advance makes it possible to perform apheresis more quickly and efficiently with less stress for the patient. This application also discloses important advances in apheresis for therapeutic treatments, including treatments for sepsis and AKI using whole blood apheresis, and immunotherapy where targets that interfere with recovery are removed by apheresis and gene-engineered fragments previously removed are reintroduced. Use of selective withdrawal through apheresis expands possible resolutions of illnesses and conditions previously thought to be untreatable.

A composition including albumin for use in the treatment of Amyotrophic Lateral Sclerosis (ALS), wherein the composition is administrated to the patient by plasma exchange using a volume of the composition equivalent to approximately 100% of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total period of 24 weeks.

A method and system for scheduling a patient-specific immunotherapy procedure. The method includes receiving a request on a server computing device to schedule a leukapheresis appointment for an available date and time displayed on a calendar stored in a database that is in communication with the computing device. The request can be made with a client computing device that is in communication with the server computing device via a network. Furthermore, the calendar may be updated in real time by the server computing device to show any changes to the calendar. The server computing device may automatically generate a final product date to estimate when the final product of engineered cells from the patient will be available for infusion into the patient. A manufacturing processing status for the final product of engineered cells from the patient may be updated on the calendar.

An embodiment provides a method for treating a body fluid of a patient with an inflammatory cytokine storm, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody -antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

An embodiment provides a method for treating a body fluid, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

A blood isolation and extraction method includes: providing a predetermined amount of blood; utilizing a platelet filter unit to filter the predetermined amount of blood to generate a filtered blood; utilizing a plasma separation unit to divide the filtered blood into a plasma layer and a blood cell layer for separating blood cells from blood plasma; and extracting the blood plasma from the plasma layer and the blood cells from the blood cell layer. In another embodiment, the blood isolation and extraction method further includes: providing a platelet-washing unit to wash the platelet filter unit with a solution to produce a platelet solution; and mixing the platelet solution with the blood plasma to produce a platelet and plasma mixed solution.

Conventional single fraction 20-Gy broadbeam photonbeam or protonbeam chemo-radiosurgery does not sterilize EMT-MET cancer stem cell radiodurans but single fraction 100 to 10,000 Gy microbeam radiosurgery sterilizes them. Device and methods for microbeam chemo-radiosurgery including 250 MeV wakefield electronbeam is disclosed.

Surgery, chemotherapy and broadbeam and microbeam radiosurgery releases billions of abscopal metastasis causing, tumor specific plasma soluble proteins, cell membranes, apoptotic bodies, DNA and RNAs, exosomes like telomere-telomerase, ATM-ATM kinase and others. They and adaptive resistance to chemo-radiosurgery, paraneoplastic and non-paraneoplastic diseases causing immune complexes are removed by pulse flow combined continuous flow ultracentrifugation apheresis and immune affinity chromatography. Chemotherapy and high dose radiation exposed tumor cells and their exosomes are made sensitive to telomerase inhibiting and apoptosis inducing and least toxic epigallocatechin and to heparin bound receptors. They convert triple negative breast tumors into receptor positive tumors which open new avenues for treating most aggressive breast cancers.

The invention provides apheresis devices and their use for substantial removal of all types of cfDNA for treatment of various diseases and during perfusion of an organ and/or anatomical cavity, to limit the negative effects of circulating cfDNA during organ transplantation and thus improve the quality and survival of transplanted organs, and reduce unfavorable transplantation outcomes such as transplant dysfunction, ischemia-reperfusion injury, graft rejection, and organ failure.

The present invention relates to an organizer for releasably accommodating components of blood tube sets for different extracorporeal blood treatment options, in particular for dialysis methods, by means of a blood treatment apparatus, as well as methods for manufacturing and preparing an organizer of the invention.